Business Description
Vera Therapeutics Inc
NAICS : 325412
SIC : 2834
8000 Marina Boulevard, Suite 120, Brisbane, CA, USA, 94005
Description
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 11.81 | |||||
| Equity-to-Asset | 0.82 | |||||
| Debt-to-Equity | 0.1 | |||||
| Debt-to-EBITDA | -0.29 | |||||
| Piotroski F-Score | N/A/9 | |||||
| Altman Z-Score | 0 | |||||
| Beneish M-Score | 0 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History |
|---|
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 83.85 | |||||
| 9-Day RSI | 78.49 | |||||
| 14-Day RSI | 73.29 | |||||
| 6-1 Month Momentum % | -23.48 | |||||
| 12-1 Month Momentum % | -15.21 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 7.9 | |||||
| Quick Ratio | 7.9 | |||||
| Cash Ratio | 7.56 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History |
|---|
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -78 | |||||
| ROA % | -45.96 | |||||
| ROIC % | -1415.19 | |||||
| ROC (Joel Greenblatt) % | -1324.5 | |||||
| ROCE % | -49.81 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 3.89 | |||||
| Price-to-Tangible-Book | 4.09 | |||||
| EV-to-EBIT | -8.55 | |||||
| EV-to-EBITDA | -8.57 | |||||
| EV-to-FCF | -13.54 | |||||
| Price-to-Net-Current-Asset-Value | 4.33 | |||||
| Price-to-Net-Cash | 4.57 | |||||
| Earnings Yield (Greenblatt) % | -11.7 |
Guru Trades
See DetailsEMBED
SAVE
Insider Trades
See DetailsEMBED
SAVE
Gurus Latest Trades with NAS:VERA
Executives
EMBED
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0 | ||
| EPS (TTM) ($) | -2.19 | ||
| Beta | 0 | ||
| Volatility % | 110.26 | ||
| 14-Day RSI | 73.29 | ||
| 14-Day ATR ($) | 1.339304 | ||
| 20-Day SMA ($) | 17.518 | ||
| 12-1 Month Momentum % | -15.21 | ||
| 52-Week Range ($) | 12.285 - 37.11 | ||
| Shares Outstanding (Mil) | 27.14 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 9999 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Vera Therapeutics Inc Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||